Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCARLET-2 phase 3 trial of thrombomodulin alfa in sepsis-associated coagulopathy
MOH_2019-01-15_004789Phase 3Not yet recruiting
- Sponsor
- Asahi Kasei Corporation
- Start
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coagulopathy and sepsis comparing Active arm: ART-123 with Comparator arm: placebo (2 arms). Primary endpoint: Primary endpoint not reported. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
thrombomodulin alfa
03
Conditions
coagulopathysepsis
Beyond the preview
Go deeper on MOH_2019-01-15_004789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-01-15_004789.